德邦科技(688035.SH):眉山工廠一期產能預計2025年二季度可以投產
格隆匯2月25日丨德邦科技(688035.SH)披露投資者關係活動記錄表顯示,崑山工廠2024全面投產,產能爬坡較快,除了新能源材料產線外,新建UV膜產線也開始投產,新增產能支撐了2024年UV膜增長需求,新建DAF產線也建成開始打樣試生產。
眉山工廠一期產能預計2025年二季度可以投產,覆蓋西南地區寧德和比亞迪等客户需求,緩解了原來從煙台和崑山向眉山運輸產品距離遠的問題,成本和交付效率得到進一步優化,公司在新能源的產能佈局體系基本搭建成型。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.